Lifeforce connects menopause treatment with home blood collection, virtual clinical consultations and a broader longevity membership. Its public menopause page names estrogen options directly. The central uncertainty is how the offer at the top of that page relates to the testing and consultation descriptions farther down.
We retrieved the menopause page, hormone collection and membership overview on September 28, 2026. These are provider records, not independent evidence of reported outcomes. No membership was purchased, and no claim is made that a particular clinician, test or hormone product is available to an individual reader.
Obtain the selected program’s written testing schedule, complete price and prescription details before treating the membership headline as a full plan.
An explicit menopause program within a broader platform
The menopause page describes a virtual clinician visit, an individualized plan that may include prescription treatment and subsequent review. Its treatment cards include an estradiol patch, estradiol cream, progesterone and testosterone cream. This establishes a care offering rather than relying on the company’s educational articles.
Those cards are options for clinical consideration, not a standard bundle containing every item. The Hone review offers another example of a broad women’s health menu in which the eventual prescription must be kept separate from platform access. For Lifeforce, the specific product, quantity and charge remain matters to confirm once a clinician has assessed the relevant history and concerns.
The headline and the process describe different testing schedules
At the top of the menopause page, the offer refers to more than eleven biomarkers, three tests in the first year and two thereafter, alongside a $99 monthly figure. Later, the process describes a home draw measuring more than fifty biomarkers and retesting every three months. The page’s comparison table separately mentions the larger panel at the second draw.
These statements should stay visible as an unresolved difference, rather than being combined into an invented schedule. Ask which program the $99 offer purchases, which panel applies to each draw, and how many draws are included during the first and later years. We cannot determine the contracted schedule from this public page alone.
The general membership page cannot resolve the offer by itself
The membership overview describes a home blood draw and a clinician consultation every three months, access to hormones and pharmaceuticals, a supplement discount and health coaching. It is a second official record, but it does not establish that those general membership terms replace the menopause-specific headline or price.
For a usable estimate, request the selected plan name, initial charge, recurring billing period, included consultations and prescription costs. A discount on supplements is not evidence that they are required for estrogen care. The Fountain review shows why even a more detailed plan card needs its billing unit preserved; a convenient monthly-looking number is not sufficient to identify the purchase commitment.
A patch and a vaginal-treatment description answer different questions
The menopause treatment cards describe the estradiol cream in relation to vaginal dryness and painful intercourse, while the patch is presented for menopause symptoms more generally. The hormone collection confirms a broader prescription catalog, but the retrieved collection text does not supply a complete label for the product a particular patient would receive.
Our local-versus-systemic guide explains why the purpose and route need to be stated together. Ask whether the proposed cream is intended for local vaginal treatment, which exact product would be dispensed and whether another medicine is being considered. A shared estradiol ingredient does not make two preparations substitutes or establish their individual dosing instructions.
Biomarker and satisfaction claims are different from clinical outcomes
Lifeforce’s membership page displays percentage-based optimization claims with a qualification referring to members who began with suboptimal biomarkers. Its menopause page also presents reported quality-of-life improvement. Those descriptions do not supply this review with a controlled comparison of estrogen treatment against another provider.
The distinction is practical: a biomarker change, a self-reported experience and a reduction in illness are not the same endpoint. We have not independently assessed the underlying datasets, selection process or response rates. The questions-before-starting guide instead helps identify the reader’s concrete care question, which a clinician can discuss without relying on a platform-wide promotional percentage as a prediction.
Delivery language leaves pharmacy and follow-up details open
The menopause page advertises prescriptions delivered to the door and ongoing clinician contact. The sources reviewed do not establish a reader’s eligible location, pharmacy assignment, shipping charge, refill authorization or complete cancellation policy. They also do not establish that every medication shown belongs within the advertised membership price.
Ask for those details before comparing the offer with separately billed care such as Defy Medical. If a plan includes estrogen and another hormone, the estrogen-and-progesterone guide provides a framework for discussing the complete prescription. Membership access and an initial recommendation should not be interpreted as an authorization to start, continue or modify treatment without the treating professional’s direction.
The next useful document is a program-specific agreement
Lifeforce provides a recognizable menopause-care pathway, but the unresolved testing descriptions prevent a precise account of the package from the landing page alone. A written agreement should name the program and explain the actual panel, test frequency, consultation entitlement and medication billing without depending on several inconsistent summaries.
Use those terms, once confirmed, in the provider comparison. Keep clinical suitability separate from the appeal of home testing or coaching, and keep the exact estrogen label separate from the broader longevity catalog. That is the limit of this public-record review: it identifies the service and the questions the published descriptions leave open, without assigning a treatment or declaring a clinical winner.
Sources & reading
Source check dates appear with each record below. Provider pages describe their own services; they do not establish clinical superiority.
- Lifeforce: menopause management ↗Provider care and offer page · Checked 2026-09-28
- Lifeforce: membership overview ↗Provider membership page · Checked 2026-09-28
- Lifeforce: hormone pharmaceutical collection ↗Provider product collection · Checked 2026-09-28